Showing results (11-20 of 195) with videos related to
Sort By:
Pageof 20
Leukemia & Lymphoma|January 24, 2024
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantationCraig W Freyer, Alison Carulli, Noelle V Frey, et al.Expert Review of Anticancer Therapy|March 17, 2023
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangementCraig W Freyer, Mitchell E Hughes, Alison Carulli, et al.Hematology. American Society of Hematology. Education Program|December 14, 2011
Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversiesDavid L PorterTransplantation and Cellular Therapy|June 30, 2022
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with MyelofibrosisCraig W Freyer, Daria V Babushok, Noelle V Frey, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 21, 2023
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplantLindsey Chippendale, Craig W Freyer, Alison Carulli, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 15, 2023
Central line-associated Rhizobium radiobacter bloodstream infection in two allogeneic hematopoietic cell transplant recipientsRachel E Hartman, Craig W Freyer, Vasilios Athans, et al.Leukemia & Lymphoma|October 27, 2020
Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemiaCraig W Freyer, Chelsea E Peterson, Yun Man, et al.Therapeutic Advances in Hematology|April 5, 2013
Cellular therapy following allogeneic stem-cell transplantationAlison Rager, David L PorterComparative Cytogenetics|November 22, 2013
Cytogenetics of a parthenogenetic Arctic species of Micropsectra (Diptera, Chironomidae)David L Porter, Jon MartinExpert Opinion on Biological Therapy|November 23, 2013
CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the roadSaar Gill, David L PorterPageof 20